These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30780126)

  • 1. Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease.
    Handzlik G; Holecki M; Kozaczka J; Kukla M; Wyskida K; Kędzierski L; Pawlicki K; Duława J
    Pharmacol Rep; 2019 Apr; 71(2):183-188. PubMed ID: 30780126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness.
    Lee YH; Kim JH; Kim SR; Jin HY; Rhee EJ; Cho YM; Lee BW
    J Korean Med Sci; 2017 Jan; 32(1):60-69. PubMed ID: 27914133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques.
    Karlas T; Berger J; Garnov N; Lindner F; Busse H; Linder N; Schaudinn A; Relke B; Chakaroun R; Tröltzsch M; Wiegand J; Keim V
    World J Gastroenterol; 2015 Apr; 21(16):4894-902. PubMed ID: 25945002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY.
    Paul J; Venugopal RV; Peter L; Shetty KNK; Shetti MP
    Arq Gastroenterol; 2018; 55(1):7-13. PubMed ID: 29561981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When the liver gets stiff, the tough get moving.
    Nguyen TH; Wardell R; Chitturi S; Teoh N; Farrell G
    J Gastroenterol Hepatol; 2020 Jun; 35(6):953-959. PubMed ID: 31867782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive characterization of graft steatosis after liver transplantation.
    Karlas T; Kollmeier J; Böhm S; Müller J; Kovacs P; Tröltzsch M; Weimann A; Bartels M; Rosendahl J; Mössner J; Berg T; Keim V; Wiegand J
    Scand J Gastroenterol; 2015 Feb; 50(2):224-32. PubMed ID: 25429378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The inverse effect of meal intake on controlled attenuation parameter and liver stiffness as assessed by transient elastography.
    Ratchatasettakul K; Rattanasiri S; Promson K; Sringam P; Sobhonslidsuk A
    BMC Gastroenterol; 2017 Apr; 17(1):50. PubMed ID: 28407734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
    de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
    J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial.
    Lukenda Zanko V; Domislovic V; Trkulja V; Krznaric-Zrnic I; Turk-Wensveen T; Krznaric Z; Filipec Kanizaj T; Radic-Kristo D; Bilic-Zulle L; Orlic L; Dinjar-Kujundzic P; Poropat G; Stimac D; Hauser G; Mikolasevic I
    Diabetes Obes Metab; 2020 Nov; 22(11):2097-2106. PubMed ID: 32613718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.
    Lee HW; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Kim KJ; Han KH
    Dig Dis Sci; 2017 Aug; 62(8):2150-2158. PubMed ID: 28523578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Chan WK; Nik Mustapha NR; Mahadeva S
    J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Short-Term Vitamin D Correction on Hepatic Steatosis as Quantified by Controlled Attenuation Parameter (CAP).
    Papapostoli I; Lammert F; Stokes CS
    J Gastrointestin Liver Dis; 2016 Jun; 25(2):175-81. PubMed ID: 27308648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification.
    You SC; Kim KJ; Kim SU; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
    J Gastroenterol Hepatol; 2015 Oct; 30(10):1536-42. PubMed ID: 25973647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
    Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
    Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients.
    Vuille-Lessard É; Lebouché B; Lennox L; Routy JP; Costiniuk CT; Pexos C; Giannakis A; Szabo J; Klein MB; Sebastiani G
    AIDS; 2016 Nov; 30(17):2635-2643. PubMed ID: 27603289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
    de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
    Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with significant liver steatosis and fibrosis as assessed by transient elastography in patients with one or more components of the metabolic syndrome.
    Mikolasevic I; Milic S; Orlic L; Stimac D; Franjic N; Targher G
    J Diabetes Complications; 2016; 30(7):1347-53. PubMed ID: 27324703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Correlation Between Obesity-Related Diseases and Non-alcoholic Fatty Liver Disease in Women in the Pre-operative Evaluation for Bariatric Surgery Assessed by Transient Hepatic Elastography.
    de Barros F; Setúbal S; Martinho JM; Leite NC; Guaraná T; Monteiro ABS; Villela-Nogueira CA
    Obes Surg; 2016 Sep; 26(9):2089-2097. PubMed ID: 26803754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.